Dr. Hayley Angove joined Vernalis in 2014. As a seasoned analytical biochemist, Hayley brings over two decades of expertise to the field of early-stage drug discovery. Specializing in progressing novel targets through primary screening, Hayley employs a diverse array of biochemical assays and direct binding techniques. Career highlights include automating medium-throughput screening, designing screening campaigns, inhibitor mode-of action studies and coordinating multidisciplinary assay teams. Hayley is proficient in developing, optimizing, and validating various screening assays, including TR-FRET, FP, and coupled assays for fragment and drug-like libraries and in utilizing biophysics techniques such as MS, ITC, DSF, MS and DLS to accelerate drug development.
